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ranslational research has been a common catchword in the NIH's effort to turn 
basic research into solutions for clinical problems. Despite a range of very suc-
cessful programs in a range of medical specialties, the effort has not been largely 
successful for translational research of inner ear issues. Clinical otology currently suf-
fers from a complete lack of medications to treat what really are amongst the most 
common neurodegenerative problems in man. Sensorineural hearing loss is almost 
ubiquitous by age 70 and vertigo represents one of the most common causes of primary 
care visits in the United States.  
Compared to a similar organ system, 
the eye, there has been little true transla-
tional research despite years of basic sci-
ence research and little understanding 
within our clinical subspecialty of how to 
actually make this happen. To most, 
translational research means disease re-
search within an animal model. In this 
paper we will review our pathway to 
build a hearing and balance research in-
frastructure within the department of 
Otolaryngology Head and Neck Surgery 
at the University of Kansas Medical Cen-
ter, and how we used that infrastructure 
to translate ongoing gene therapy re-
search into human clinical trials. 
The World Health Organization re-
cently recognized the burden of hearing 
loss and estimates that 5% of the world’s 
population is disabled by this condition 
(http://www.who.int/mediacentre/fact-
sheets/fs300/en/). Currently we are lim-
ited to amplification (or in case of severe 
hearing loss, cochlear implantation) as a 
means to restore hearing. Both of these 
are helpful but not ideal solutions to this 
very common problem. Development of 
medications for inner ear disease has 
been slow due to inability to biopsy the 
inner ear for analysis and the lack of cor-
relation between clinical hearing and ves-
tibular testing and site of lesion within 
the inner ear. Additionally it is only very 
recently that genetic testing has been 
available that can identify congenital or 
adult onset progressive hearing losses 
(Shearer, DeLuca et al. 2010).  
Compared to other organ systems 
pathologic evaluation of human ear tis-
sue is complex. What we know is derived 
from human temporal bones that have 
undergone decalcification and histologic 
evaluation often years after the active dis-
ease process is passed. The biology of the 
inner ear is complex and drugs that affect 
in ear function often will also affect the 
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central nervous system, making systemi-
cally delivered medications difficult to 
apply. Basic science research has focused, 
broadly speaking, on several different re-
search strategies with translational po-
tential. These include delivery of growth 
factors to maintain our ganglion integ-
rity, use of antioxidants are process fac-
tors to protect the interview trauma and 
hair cell regeneration. 
Our lab has largely focused on the 
development of gene therapy technology 
for inner ear applications to help imple-
ment some discovery research going on 
in numerous other research groups. One 
of the relative advantages of the inner ear 
is that it can be locally accessed. Drugs 
can be delivered through the middle ear 
with diffusion of substances through the 
round window or through the stapedio-
vestibular ligament or when larger mole-
cules are involved, through direct injec-
tion into the inner ear. When we were in-
itially looking for a translational research 
project to undertake, hair regeneration 
was an easy target since we have a quan-
tifiable outcomes measure, namely the 
number of regenerated hair cells pro-
duced which could then be correlated to 
hearing or balance function.  The molec-
ular basis of hair cell regeneration has 
been established for a number of years.  
The transcription factor atonal/atoh1 is 
responsible for genesis of hair cells dur-
ing development in vertebrates. Multiple 
researchers have demonstrated that the 
overexpression of atoh1 results in genesis 
of hair cells that are innervated and show 
recovery of function in mammalian mod-
els of ototoxicity(Baker, Brough et al. 
2009). Delivery of atoh1 therefore could 
be a target for a translational research 
program.  
When the project was undergoing its 
initial development phase we decided to 
target balance disorders caused by ami-
noglycoside ototoxicity. Patients who re-
ceived gentamicin or other aminoglyco-
sides for severe infections often end up 
with bilateral vestibular hypofunction 
despite adequate monitoring of blood 
aminoglycoside levels. Since we know 
the mechanism by which aminoglyco-
sides damaged hair cells, a patient with 
loss of vestibular function with a history 
of aminoglycoside usage can be identi-
fied as a target for hair cell regeneration. 
An additional advantage of targeting the 
vestibular system is that there is no coch-
lear implant equivalent yet. 
Despite early successes in regenerat-
ing hair cells in animal models of both 
hearing loss and vestibular dysfunction, 
numerous hurdles remained in the devel-
opment process. Moving a drug candi-
date forward required calculation of dose 
response curves and understanding of 
the dosing relationships within the lim-
ited space of the inner ear. Additionally, 
analysis of potential downstream compli-
cations and longevity of regenerated hair 
cells had to be conducted. Animal hair 
cell loss models and drug delivery mod-
els had to be modified so that they could 
be used in contract research organiza-
tions where repeated experiments using 
GMP developed vector and GLP prac-
tices could be carried out. The record-
keeping and expense associated with this 
is generally outside of the ability of the 
basic research lab. Funding of these type 
of experiments is difficult, since it is not 
really discovery research and many 
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study sections think that this type of re-
search should be done by pharmaceutical 
companies. However, pharmaceutical 
companies will not pick up a potential 
product until this type of data is available 
to them at least in an early form. 
In parallel to drug development efforts 
we had to establish a program for conduct-
ing clinical trials for inner ear disorders. 
Most clinical trial organizations or sections 
within the university hospital where clinical 
trials are conducted lack the ability to evalu-
ate hearing and balance disorders. This is 
mainly due to the complex equipment and 
infrastructure needed to perform these 
types of evaluations. As always, putting 
new infrastructure in place requires fund-
ing. We set out to establish a hearing clinical 
trials program in 2007. Our initial efforts tar-
geted device trials such as cochlear implants 
and implantable hearing aids. This pro-
vided the funding to cover the cost of an au-
diologist to perform testing and screen pa-
tients. The establishment of the hearing clin-
ical trial program was overseeing by Kevin 
Sykes (co-author). He had an appointment 
to the institutional review board (IRB) and 
initially oversaw integrity data collection 
and managed contacts. Our experience with 
running device trials and having infrastruc-
ture in place for hearing testing and a full-
time liaison to the research office allowed us 
to attract early-stage drug clinical trials for 
tinnitus and Ménière’s disease. We then 
added a research fellow, generally a student 
who had completed college and wanted to 
spend a year in clinical research, to help 
manage the growing number of patients. In 
2012 we hired a full-time research nurse 
which was needed to launch the gene ther-
apy clinical trial. The growth in income from 
otology clinical trials during this time is 
shown in Figure 1.  
In addition to covering the otology 
trials, putting clinical trial infrastructure 
into place has also opened opportunities 
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Figure 1: Income derived from the KU Otology clinical trial program over time. 
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for other subspecialties within otolaryn-
gology to provide clinical trials and bring 
in income to grow the academic mission. 
Establishing an infrastructure for com-
plex trials such as inner ear gene therapy 
is vital, since these are high-risk trials that 
require time-consuming applications to 
the institutional IRB and prolonged con-
tract negotiations with the trial sponsor. 
Additional staffing is also required to 
manage the flow of patients. Our current 
gene therapy trial requires two pretreat-
ment visits and monthly visits for six 
months after delivery of the drug. Each of 
these visits takes two days, therefore 
scheduling and ensuring that audiologi-
cal resources are available, especially 
when patients start to overlap, is im-
portant. All of this cannot be done by a 
lone clinician.  
Having put a hearing research pro-
gram together, we are now able to attract 
the interest of both preclinical and clinical 
stage research programs. The basic sci-
ence lab has a subcontract with an early 
stage pharmaceutical company that is 
looking at our expertise in animal model-
ing to test a new nano particle for drug 
delivery to the middle ear space. The clin-
ical research unit is now involved with 
two new phase 3 trials for tinnitus and for 
Ménière’s disease. It is only due to our 
publication record and our track record 
of working with several contract research 
organization and being able to provide 
clinical material for a number of trials 
that we are able to do this. Academic in-
stitutions generally cannot compete with 
private institutions that make money 
from clinical trials.  
Most of the private providers of 
these services focus on straightforward 
internal medicine type clinical trials and 
are competitive because of lower over-
head costs and more straightforward 
contract negotiations with the sponsor. 
Many of these institutions also use pri-
vate IRBs which are often more straight-
forward to navigate than a University 
IRB. The advantage of being an academic 
center is that we have a large base of pa-
tients with a number of rare diseases, and 
have infrastructure to support the testing 
and treatment of these diseases. This is 
true not only of neurotology but other 
subspecialties as well.  Establishment of a 
successful translational research program 
requires a track record and most of all, an 
experienced and dedicated support 
structure. 
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